share_log

Novavax | DEF 14A: Definitive information statements

Novavax | DEF 14A: Definitive information statements

诺瓦瓦克斯医药 | DEF 14A：股东委托书决议
美股sec公告 ·  04/29 07:57
Moomoo AI 已提取核心信息
Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
专门从事创新疫苗发现、开发和商业化的生物技术公司Novavax, Inc.（NVAX）宣布修订和重述其2015年股票激励计划和2013年员工股票购买计划。修正案须经股东批准，提议增加这两个计划下可供发行的股票数量。2015年的股票激励计划要求增加650万股，而员工股票购买计划则要求增加1,000,000股。这些变化旨在通过股权所有权使员工的利益与股东的利益保持一致，从而吸引、留住和激励员工。该公告是为定于2024年6月13日举行的Novavax2024年年度股东大会做准备的，届时股东将对这些提案和其他提案进行投票，包括选举董事和批准安永会计师事务所作为截至2024年12月31日的财年的公司独立审计师。
专门从事创新疫苗发现、开发和商业化的生物技术公司Novavax, Inc.（NVAX）宣布修订和重述其2015年股票激励计划和2013年员工股票购买计划。修正案须经股东批准，提议增加这两个计划下可供发行的股票数量。2015年的股票激励计划要求增加650万股，而员工股票购买计划则要求增加1,000,000股。这些变化旨在通过股权所有权使员工的利益与股东的利益保持一致，从而吸引、留住和激励员工。该公告是为定于2024年6月13日举行的Novavax2024年年度股东大会做准备的，届时股东将对这些提案和其他提案进行投票，包括选举董事和批准安永会计师事务所作为截至2024年12月31日的财年的公司独立审计师。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息